Lessons learned from mouse models of hemolytic transfusion reactions

Current Opinion in Hematology

Volumn 15, Issue 6, 2008, Pages 601-605

  Hod, Eldad A ^a   Zimring, James C ^b   Spitalnik, Steven L ^a,c  

^a NewYork Presbyterian Hospital   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Columbia University ^*  (United States)

Author keywords

Antigen loss; Cytokines; Hemolysis; Hemolytic transfusion reaction

Indexed keywords

ALLOANTIBODY; ANTIGEN; CLODRONIC ACID; CYTOKINE; GLYCOPHORIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYSOZYME; MONOCLONAL ANTIBODY; NITRIC OXIDE; PEPTIDE DERIVATIVE;

AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD GROUP DUFFY SYSTEM; BLOOD GROUP INCOMPATIBILITY; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CROSS LINKING; EGG; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MEMBRANE POTENTIAL; NEW ZEALAND BLACK MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ANIMALS; BLOOD TRANSFUSION; CYTOKINES; DISEASE MODELS, ANIMAL; HEMOLYSIS; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC;

EID: 55149097871     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328311f40a     Document Type: Review

References (48)

1. Capon SM, Goldfinger D. Acute hemolytic transfusion reaction, a paradigm of the systemic inflammatory response: new insights into pathophysiology and treatment. Transfusion 1995; 35:513-520.
2. Pineda AA, Vamvakas EC, Gorden LD, et al. Trends in the incidence of delayed hemolytic and delayed serologic transfusion reactions. Transfusion 1999; 39:1097-1103.
3. Diamond WJ, Brown FL Jr, Birterman P, et al. Delayed hemolytic transfusion reaction presenting as sickle-cell crisis. Ann Intern Med 1980; 93:231-234.
4. Milner PF, Squires JE. Posttransfusion crises in sickle cell anemia. Prog Clin Biol Res 1987; 240:351-359.
5. Cox JV, Steane E, Cunningham G, et al. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch Intern Med 1988; 148:2485-2489.
6. King KE, Shirey RS, Lankiewicz MW, et al. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells. Transfusion 1997; 37:376-381.
7. Atkinson JP, Frank MM. Complement-independent clearance of IgG-sensitized erythrocytes: inhibition by cortisone. Blood 1974; 44:629-637.
8. Auer L, Bell K, Coates S. Blood transfusion reactions in the cat. J Am Vet Med Assoc 1982; 180:729-730.
9. Hardaway RM 3rd, McKay DG, Wahle GH Jr, et al. Pathologic study of intravascular coagulation following incompatible blood transfusion in dogs. I. Intravenous injection of incompatible blood. Am J Surg 1956; 91:24-31.
10. Lopas H, Birndorf NI, Bell CE Jr, et al. Experimental transfusion reactions in monkeys: haemolytic, coagulant and renal effects of transfused isoimmune IgG and IgM. BrJ Haematol 1972; 23:765-776.
11. Ness PM, Shirey RS, Weinstein MH, et al. An animal model for delayed hemolytic transfusion reactions. Transfus Med Rev 2001; 15:305-317.
12. Schreiber AD, Frank MM. Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J Clin Invest 1972; 51:575-582.
13. Amos DB, Zumpft M, Armstrong P. H-5.A and H-6.A, two mouse isoantigens on red cells and tissues detected serologically. Transplantation 1963; 1:270-283.
14. Azen EA, Davisson MT, Cherry M, et al. Prp (proline-rich protein) genes linked to markers Es-12 (esterase-12), Ea-10 (erythrocyte alloantigen), and loci on distal mouse chromosome 6. Genomics 1989; 5:415-422.
15. Ferreira A, David CS, Nussenzweig V. The murine H-2.7 specificity is an antigenic determinant of C4d, a fragment of the fourth component of the complement system. J Exp Med 1980; 151:1424-1435.
16. Stimpfling JH, Reichert AE, Blanchard S. Gentic control of the immune response to the Ea-2 alloantigen system of the mouse. I. The humoral antibody response. J Immunol 1976; 116:1096-1098.
17. Erickson RP, Herzenberg LA, Goor R. Partial immune elimination of homologous red blood cells in mice. Transplantation 1964; 2:175-182.
18. Moller G. Biologic properties of 19 S and 7 S mouse isoantibodies directed against isoantigens of the H-2 system. J Immunol 1966; 96:430-439.
19. Bazin R, Aubin E, Boyer L, et al. Functional in vivo characterization of human monoclonal anti-D in NOD-scid mice. Blood 2002; 99:1267-1272.
20. Yazdanbakhsh K, Kang S, Tamasauskas D, et al. Complement receptor 1 inhibitors for prevention of immune-mediated red cell destruction: potential use in transfusion therapy. Blood 2003; 101:5046-5052.
21. Campbell-Lee SA, Liu J, Velliquette RW, et al. The production of red blood cell alloantibodies in mice transfused with blood from transgenic Fyb-expressing mice. Transfusion 2006; 46:1682-1688.
22. Hsu LL, Champion HC, Campbell-Lee SA, et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 2007; 109:3088-3098. This study suggests that impairment of the nitric oxide system and endothelial cell dysfunction plays a role in the pathophysiology of HTRs.
23. Schirmer DA, Song SC, Baliff JP, et al. Mouse models of IgG- and IgM-mediated hemolysis. Blood 2007; 109:3099-3107. This study showed importance of antibody isotype and IgG subclass in mechanism of RBC clearance in an in-vivo mouse HTR model. First example of IgM-mediated intravascular hemolysis associated with gross hemoglobinuria in a mouse model.
24. Hod EA, Cadwell CM, Liepkalns JS, et al. Cytokine storm in a mouse model of IgG-mediated hemolytic transfusion reactions. Blood 2008; 112:891-894. Implicated cytokine storm in vivo in the pathophysiology of IgG-mediated HTRs with therapeutic implications.
25. Zimring JC, Cadwell CM, Chadwick TE, et al. Nonhemolytic antigen loss from red blood cells requires cooperative binding of multiple antibodies recognizing different epitopes. Blood 2007; 110:2201-2208. Elucidation of the antibody/antigen interactions necessary to induce the antigen loss phenomenon. May suggest ways in which RBC opsonization by antibody can be driven towards antigen loss rather than towards an HTR.
26. Zimring JC, Hair GA, Chadwick TE, et al. Nonhemolytic antibody-induced loss of erythrocyte surface antigen. Blood 2005; 106:1105-1112.
27. Cadwell CM, Zimring JC. Cross-linking induces nonhaemolytic antigen-loss from transfused red blood cells: a potential role for rheumatoid factor. Vox Sang 2008; 95:159-162. Confirmation of antigen crosslinking as a requirement for the antigen loss phenomenon. Describes novel hypothesis suggesting that rheumatoid factor affects the outcome of RBC opsonization with alloantibody/autoantibody.
28. Luo H, Chaudhuri A, Zbrzezna V, et al. Deletion of the murine Duffy gene (Dfy) reveals that the Duffy receptor is functionally redundant. Mol Cell Biol 2000; 20:3097-3101.
29. Arimitsu N, Akimitsu N, Kotani N, et al. Glycophorin A requirement for expression of O-linked antigens on the erythrocyte membrane. Genes Cells 2003; 8:769-777.
30. Thall AD. Generation of alpha 1,3galactosyltransferase deficient mice. Subcell Biochem 1999; 32:259-279.
31. Thall AD, Murphy HS, Lowe JB. Alpha 1,3-Galactosyltransferase-deficient mice produce naturally occurring cytotoxic anti-Gal antibodies. Transplant Proc 1996; 28:556-557.
32. LaTemple DC, Galili U. Adult and neonatal anti-Gal response in knock-out mice for alpha 1,3galactosyltransferase. Xenotransplantation 1998; 5:191-196.
33. Chen CG, Salvaris EJ, Romanella M, et al. Transgenic expression of human alpha 1,2-fucosyltransferase (H-transferase) prolongs mouse heart survival in an ex vivo model of xenograft rejection. Transplantation 1998; 65:832-837.
34. Sharma A, Okabe J, Birch P, et al. Reduction in the level of Gal(alpha1,3)Gal in transgenic mice and pigs by the expression of an alpha(1.2)fucosyltransferase. Proc Natl Acad Sci U S A 1996; 93:7190-7195.
35. Sandrin MS, Fodor WL, Mouhtouris E, et al. Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nat Med 1995; 1:1261-1267.
36. Cohney S, McKenzie IF, Patton K, et al. Down-regulation of Gal alphad(1,3)Gal expression by alpha 1,2-fucosyltransferase: further characterization of alpha 1,2-fucosyltransferase transgenic mice. Transplantation 1997; 64:495-500.
37. McKenzie IF, Li YQ, Patton K, et al. Fucosyl transferase (H) transgenic heart transplants to Gal-/- mice. Transplantation 2000; 70:1205-1209.
38. Baudino L, Azeredo da Silveira S, Nakata M, et al. Molecular and cellular basis for pathogenicity of autoantibodies: lessons from murine monoclonal autoantibodies. Springer Semin Immunopathol 2006; 28:175-184.
39. Jordan MB, van Rooijen N, Izui S, et al. Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model. Blood 2003; 101:594-601.
40. Mqadmi A, Zheng X, Song J, et al. Prevention of complement-mediated immune hemolysis by a small molecule compound. Biochem Biophys Res Commun 2004; 325:1465-1471.
41. Baxter AG, Mandel TE. Hemolytic anemia in nonobese diabetic mice. Eur J Immunol 1991; 21:2051-2055.
42. Oldenburg PA, Gresham HD, Chen Y, et al. Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice. Blood 2002; 99:3500-3504.
43. Barker RN, Shen CR, Elson CJ. T-cell specificity in murine autoimmune haemolytic anaemia induced by rat red blood cells. Clin Exp Immunol 2002; 129:208-213.
44. Sharon R, Naor D. Experimental model of autoimmune hemolytic anemia induced in mice with levodopa. Clin Immunol Immunopathol 1989; 52:160-172.
45. Scott BB, Sadigh S, Stow M, et al. Molecular mechanisms resulting in pathogenic antimouse erythrocyte antibodies in New Zealand black mice. Clin Exp Immunol 1993; 93:26-33.
46. de Sa Oliveira GG, Izui S, Ravirajan CT, et al. Diverse antigen specificity of erythrocyte-reactive monoclonal autoantibodies from NZB mice. Clin Exp Immunol 1996; 105:313-320.
47. Mathes M, Jordan M, Dow S. Evaluation of liposomal clodronate in experimental spontaneous autoimmune hemolytic anemia in dogs. Exp Hematol 2006; 34:1393-1402.
48. Yu J, Heck S, Debnath A, et al. Identification of a complement receptor 1 peptide for inhibition of immune hemolysis. Biochem Biophys Res Commun 2007; 353:363-368. A novel therapeutic approach using mouse models of HTRs.